Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.
Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.
Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.
The Board of Directors of Zoetis (NYSE:ZTS) has declared a dividend of $0.375 per share for Q2 2023. This dividend will be distributed on June 1, 2023, to shareholders on record as of April 21, 2023. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021. With over 70 years of experience, they provide innovative solutions for animal care globally.
For more information on their products and services, visit www.zoetis.com.
Zoetis Inc (NYSE:ZTS) will hold a webcast and conference call on February 14, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present and answer questions from analysts. Investors can access the live webcast via the Zoetis website and a replay will be available following the event. Zoetis, a leading global animal health company, reported $7.8 billion in revenue for 2021 and continues to innovate in animal care across over 100 countries.
Zoetis (NYSE: ZTS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. CEO Kristin Peck is scheduled to present at 1:30 p.m. PT and answer analyst questions. Investors can access a live audio webcast of the presentation through the company's investor relations site. A replay will also be available post-event. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries, focusing on animal care and health innovations.
The Board of Directors of Zoetis has announced a dividend of $0.375 per share for Q1 2023, marking a 15% increase from 2022. This dividend will be paid on March 1, 2023, to shareholders on record as of January 20, 2023. Executive VP and CFO Wetteny Joseph highlighted the company's robust product portfolio and global presence as key factors for generating increased cash flow for future investments and returning capital to shareholders.
Zoetis (NYSE:ZTS) will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022. Glenn David, Executive Vice President and Group President of U.S. Operations, will present at 3:30 p.m. ET. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations. A replay will be available post-event. As a leading animal health company, Zoetis aims to improve animal care globally, generating $7.8 billion in revenue in 2021.
Zoetis Inc. (NYSE:ZTS) has announced a public offering of $1.35 billion in senior notes, which includes $600 million of 5.400% notes due in 2025 and $750 million of 5.600% notes due in 2032. The proceeds will be used to repay existing 3.250% senior notes due in 2023. The offering is anticipated to close on November 16, 2022, subject to standard conditions. Barclays Capital, BofA Securities, Citigroup, J.P. Morgan, and MUFG are the joint book-running managers for the offering. The securities are registered under the Securities Act of 1933.
Zoetis reported Q3 2022 revenue of $2.0 billion, a 1% increase year-over-year, with net income at $529 million or $1.13 per diluted share, reflecting decreases of 4% and 3%, respectively. Operational growth was strong, with a 5% revenue rise and 2% adjusted net income increase. The company has lowered its full-year revenue guidance to $8.000 - $8.075 billion due to supply constraints and foreign exchange impacts. Key product sales in the companion animal segment showed promise, though livestock product sales faced challenges.
Vyond has announced its Fall Release of Vyond Studio, enhancing enterprise video creation through AI integration. The new features enable businesses to produce videos up to 10X faster and 130% more engaging than traditional methods. Users can now import SVG files, utilize advanced charts, and access AI-powered tools such as Instant Video Translation into 71 languages. These updates aim to improve communication in HR, Sales, and Marketing, empowering companies like Zoetis to streamline onboarding and training initiatives.
Zoetis Inc. (NYSE:ZTS) has declared a $0.325 per share dividend for Q4 2022, payable on December 1, 2022, to shareholders on record as of November 1, 2022. With a revenue of $7.8 billion in 2021, Zoetis is a leader in animal health, driven by innovation in animal care over 70 years. Their portfolio includes medicines, vaccines, and diagnostics for animals worldwide. This dividend reflects the company's commitment to providing returns to investors while sustaining growth.
Zoetis has been awarded a spot on Fortune’s 2022 Change the World list, ranking 20th among 50 companies recognized for their positive social impact. This recognition stems from Zoetis’ African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, which has significantly improved veterinary care access in Sub-Saharan Africa over the past five years. Key achievements include:
- 91 veterinary products available
- 128 million animals treated
- 16 operational diagnostic labs
- 26,000 trained individuals in veterinary care
